PRODUCT INFORMATION

ATB-346
Item No. 16234

CAS Registry No.: 1226895-20-0
Formal Name: 6-methoxy-α-methyl-2-naphthaleneacetic acid, 4-(aminothioxomethyl)phenyl ester
MF: C21H19NO3S
FW: 365.5
Purity: ≥ 98%
UV/Vis.: λmax: 231 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥ 2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ATB-346 is supplied as a crystalline solid. A stock solution may be made by dissolving the ATB-346 in the solvent of choice. ATB-346 is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

ATB-346 is a non-steroidal anti-inflammatory drug (NSAID), derived from naproxen but coupled to an H2S-releasing moiety.1 At 30 µmol/kg in rats, it suppressed COX and gastric PGE2 synthesis to the same level as naproxen but reduced COX-2 expression and accelerated recovery in a rat spinal cord injury model.2 It also provided enhanced anti-inflammatory and antinociceptive activity over naproxen in a rat model of arthritis.3 ATB-346 does not induce gastrointestinal toxicity and, in contrast to other NSAIDs, it accelerated healing of pre-existing gastric ulcers.4 Studies of ATB-346 have shown promising results in vitro and in animal models of melanoma and intestinal tumorogenesis.5,6 A Phase I clinical trial in Canada did not find any significant gastrointestinal, cardiovascular, renal, or hematological findings across dose ranges in healthy adults (25 mg–2,000 mg once/d).7 A Phase II trial in Canada is ongoing for patients with osteoarthritis of the knee.

Examples